Michael Okunewitch
Stock Analyst at Maxim Group
(0.09)
# 4,849
Out of 5,162 analysts
399
Total ratings
30.4%
Success rate
-9.3%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Maintained: Buy | $200 | $157.35 | +27.11% | 15 | Nov 17, 2026 | |
| AZR Azora Therapeutics | Maintained: Buy | $12 | $3.88 | +209.28% | 2 | Nov 17, 2026 | |
| KPRX Kiora Pharmaceuticals | Maintained: Buy | n/a | $1.52 | - | 35 | Nov 14, 2026 | |
| MDWD MediWound | Reiterated: Buy | $30 | $14.20 | +111.27% | 29 | Nov 14, 2026 | |
| DFTX Definium Therapeutics | Maintained: Buy | $55 | $35.29 | +55.85% | 18 | Nov 14, 2026 | |
| RANI Rani Therapeutics Holdings | Maintained: Buy | $5 | $0.5731 | +772.45% | 17 | Nov 12, 2026 | |
| OCGN Ocugen | Maintained: Buy | $8 | $0.9734 | +721.86% | 25 | Nov 11, 2026 | |
| ACRV Acrivon Therapeutics | Maintained: Buy | $7 | $1.57 | +345.86% | 14 | Nov 10, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | n/a | $9.20 | - | 13 | Nov 5, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | n/a | $169.39 | - | 25 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $2.72 | +414.71% | 6 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.5574 | +617.62% | 14 | Oct 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $3.90 | +797.44% | 1 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.00 | +700.00% | 26 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.61 | - | 24 | Oct 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.1979 | - | 3 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.06 | - | 26 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.2001 | - | 4 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $1.09 | +175.23% | 16 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.32 | +278.79% | 13 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.95 | - | 8 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $12 | $1.40 | +757.14% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $0.8442 | +1,676.83% | 7 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.6823 | - | 6 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.5266 | n/a | 28 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6.9 | $1.42 | n/a | 6 | Sep 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.50 | n/a | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.54 | n/a | 11 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.2007 | n/a | 4 | May 9, 2023 |
Belite Bio
Nov 17, 2026
Maintained: Buy
Price Target: $200
Current: $157.35
Upside: +27.11%
Azora Therapeutics
Nov 17, 2026
Maintained: Buy
Price Target: $12
Current: $3.88
Upside: +209.28%
Kiora Pharmaceuticals
Nov 14, 2026
Maintained: Buy
Price Target: n/a
Current: $1.52
Upside: -
MediWound
Nov 14, 2026
Reiterated: Buy
Price Target: $30
Current: $14.20
Upside: +111.27%
Definium Therapeutics
Nov 14, 2026
Maintained: Buy
Price Target: $55
Current: $35.29
Upside: +55.85%
Rani Therapeutics Holdings
Nov 12, 2026
Maintained: Buy
Price Target: $5
Current: $0.5731
Upside: +772.45%
Ocugen
Nov 11, 2026
Maintained: Buy
Price Target: $8
Current: $0.9734
Upside: +721.86%
Acrivon Therapeutics
Nov 10, 2026
Maintained: Buy
Price Target: $7
Current: $1.57
Upside: +345.86%
COMPASS Pathways
Nov 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.20
Upside: -
Gilead Sciences
Nov 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $169.39
Upside: -
Nov 2, 2026
Reiterated: Buy
Price Target: $14
Current: $2.72
Upside: +414.71%
Oct 27, 2026
Reiterated: Buy
Price Target: $4
Current: $0.5574
Upside: +617.62%
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $3.90
Upside: +797.44%
Oct 9, 2026
Reiterated: Buy
Price Target: $8
Current: $1.00
Upside: +700.00%
Oct 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.61
Upside: -
Oct 2, 2026
Rated: Buy
Price Target: n/a
Current: $0.1979
Upside: -
Sep 18, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.06
Upside: -
Aug 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.2001
Upside: -
Aug 11, 2026
Reiterated: Buy
Price Target: $3
Current: $1.09
Upside: +175.23%
Jul 13, 2026
Reiterated: Buy
Price Target: $5
Current: $1.32
Upside: +278.79%
May 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.95
Upside: -
Apr 9, 2026
Rated: Buy
Price Target: $10 → $12
Current: $1.40
Upside: +757.14%
Mar 25, 2026
Reiterated: Buy
Price Target: $15
Current: $0.8442
Upside: +1,676.83%
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.6823
Upside: -
Sep 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.5266
Upside: n/a
Sep 13, 2025
Reiterated: Hold
Price Target: $6.9
Current: $1.42
Upside: n/a
Mar 3, 2025
Reiterated: Buy
Price Target: $12
Current: $2.50
Upside: n/a
Sep 13, 2024
Reiterated: Buy
Price Target: $12
Current: $4.54
Upside: n/a
May 9, 2023
Reiterated: Buy
Price Target: n/a
Current: $0.2007
Upside: n/a